tirzepatide and kidney disease improves outcomes in T2DM with increased CV risk It's important to study the

During clinical trials, 30% of adults and 22% of adolescents reported diarrhea while taking Wegovy injection

This means reports of optic nerve injury appeared far more frequently with Wegovy than researchers would expect to see by chance alone

Early research suggests GLP-1 may influence immune signalling and inflammation in the pelvic environment

The sections below cover Phase 3 and Phase 2 trial data, a month-by-month timeline of what weight loss looks like in practice, how results compare to tirzepatide and semaglutide, and the factors that determine where you personally land in the range

The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks

Gain the advantages of improved mood, increased energy, and metabolism control